{"entity":{"id":"blood-cell-variants-liquid-biopsy","kind":"term","name":"Blood-cell variants in liquid biopsy","aka":["clonal hematopoiesis and plasma variant origin","white blood cell sequencing for cfDNA interpretation"],"tldr":"A DNA change found in plasma may come from blood cells rather than a tumor. Establishing where a change came from is part of interpreting a liquid biopsy.","summary":"A primary study compared plasma cell-free DNA, matched white blood cells and tumor samples and found substantial contributions from clonal hematopoiesis to plasma variants. Matched blood-cell sequencing helped attribute origin. A technically real somatic variant is not necessarily tumor-derived, and origin cannot be assigned from the gene name alone. This measurement problem is distinct from assessing the future health implications of a blood-cell clone.","asOf":"2026-11-10","links":[{"label":"Matched plasma, blood-cell and tumor sequencing study (2019)","url":"https://doi.org/10.1038/s41591-019-0652-7"},{"label":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","url":"https://doi.org/10.1038/s41588-020-00710-0"},{"label":"Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes","url":"https://doi.org/10.1056/NEJMoa1408617"}],"tags":[],"related":["ctdna","vaf","analytical-vs-clinical-validation"],"cancers":[],"sections":[],"technologies":["liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["clonal-haematopoiesis"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["How common it is: in paired plasma and white-blood-cell sequencing, 53.2% of cfDNA mutations in 124 people with metastatic cancer and 81.6% in 47 people without cancer had features of clonal haematopoiesis, and variants that could not be separated from white-blood-cell DNA kept an explicit ambiguous category (Razavi 2019). Blood-cell clones also fall into gene groups: DNMT3A, TET2 and ASXL1 with age (Jaiswal 2014) and TP53, PPM1D and CHEK2 selected by radiation, platinum and topoisomerase II inhibitors (Bolton 2020). A gene often mutated in tumours is therefore not proof of tumour origin.","Attribution rule: matched white-blood-cell sequencing is the standard comparison, but its gene coverage, depth and detection rules matter, a clone below its sensitivity can stay unseen, and subtracting every blood match is not a complete method because a variant can be present in blood and tumour. In a fictional case the same variant V is detected in plasma and blood cells and not in the sampled tumour. That supports a blood-cell contribution, and tumour non-detection is not a biological zero because it is bounded by coverage, sensitivity, timing and the region sampled."],"category":"Biomarkers"},"route":"/terms/blood-cell-variants-liquid-biopsy/","neighbours":{"term":[{"id":"analytical-vs-clinical-validation","kind":"term","name":"Analytical versus clinical validation","route":"/terms/analytical-vs-clinical-validation/"},{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"measurement-to-benefit-evidence","kind":"term","name":"Evidence from measurement to patient benefit","route":"/terms/measurement-to-benefit-evidence/"},{"id":"vaf","kind":"term","name":"Variant allele frequency (VAF)","route":"/terms/vaf/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"}],"pathway":[{"id":"clonal-haematopoiesis","kind":"pathway","name":"Clonal haematopoiesis (CHIP)","route":"/pathways/clonal-haematopoiesis/"}]}}